| Primary information |
|---|
| sequence ID | Seq_7183 |
| Peptide sequence | SHALQLNNRQIR |
| CancerPDF_ID | CancerPDF_ID882, CancerPDF_ID1919, CancerPDF_ID3161, CancerPDF_ID9467, CancerPDF_ID12191, |
| PMID | 19795908,21136997,21136997,26379225,26992070 |
| Protein Name | Complement C4-B,Complement C4-B,Complement C4-A,Complement C4-A/Complement C4-B,Complement C4-B |
| UniprotKB Entry Name | CO4B_HUMAN,CO4B_HUMAN,CO4A_HUMAN,"CO4A_HUMAN,CO4B_HUMAN",CO4B_HUMAN |
| Fluid | Plasma,Serum,Plasma,Plasma,Serum |
| M/Z | 725.4,1448.79604,1448.796,1449.77,1448.796 |
| Charge | 2,1,1,NA,NA |
| Mass (in Da) | NA,NA,NA,NA,NA |
| fdr | NA,NA,NA,NA,NA |
| Profiling Technique | LC-MS,LC-MS,LC-MS,MALDI-TOF,LC-MS |
| Peptide Identification technique | MALDI-TOF/TOF,LC-MS-MS/MS,LC-MS-MS/MS,MALDI-TOF/TOF,LC-MS/MS |
| Quantification Technique | LC-MRM (multiple reaction monitoring),LC-ESI-MS,LC-ESI-MS,NA,NA |
| Labelled/Label Free | Labelled,Label Free,Label Free,Label Free,Label Free |
| FDR | less than 7%,NA,NA,NA,FDR 1 % |
| CancerPDF_ID | CancerPDF_ID882, CancerPDF_ID1919, CancerPDF_ID3161, CancerPDF_ID9467, CancerPDF_ID12191, |
| p-Value | NA,NA,NA,NA,NA |
| Software | FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT (v 2.3),SEQUEST and Maxquant |
| Length | 12,12,12,12,12 |
| Cancer Type | Ductal adenocarcinoma of the pancreas (DAP),Colorectal cancer,Normal,Colorectal cancer,Melanoma |
| Database | NCBI refseq Protein Database,SwissProt Database,SwissProt Database,UniprotKB,SwissProt Database |
| Modification | NA,NA,NA,NA,NA |
| Number of Patients | "42 normal, 28 patients",30 patients and 30 healthy controls,27 healthy individuals,"94 patients with CRC, 23 with liver metastasis from CRC (histologically defined) and 34 subjects, which underwent colonoscopy and resulted negative",8 cancer samples and 4 healthy samples |
| Regulation | NA,NA,NA,Lower intensity in liver metastasis group than adenoma and CRC groups,"Present in 6 cancer samples out of 8 cancer samples. ,Present in 3 healthy samples out of 4 healthy samples." |
| Validation | NA,Leave One out Cross validation,Leave One out Cross validation,NA,na |
| Sensitivity | NA,NA,NA,NA,NA |
| Specificity | NA,NA,NA,NA,NA |
| Accuracy | NA,NA,NA,NA,NA |
| Peptide Atlas | NA |
| IEDB | |